-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Repligen, Raises Price Target to $225

Benzinga·09/09/2026 17:56:07
Listen to the news
UBS analyst Dan Leonard maintains Repligen (NASDAQ:RGEN) with a Buy and raises the price target from $195 to $225.